Last updated: September 5, 2026
Ciltacabtagene autoleucel, marketed as Carvykti by Janssen Biotech and Legend Biotech, is one of the fastest-growing multiple myeloma therapies. U.S. approval expanded from heavily pretreated disease in 2022 to earlier-line treatment in 2024, materially increasing the addressable market. Global sales rose from about $500 million in 2023 to roughly $1 billion in 2024, driven by stronger demand, broader eligibility, and manufacturing expansion. The main commercial constraints are production capacity, treatment-center throughput, inpatient monitoring, and the safety profile of BCMA-directed CAR-T therapy.
What is ciltacabtagene autoleucel and how does Carvykti work?
Ciltacabtagene autoleucel is an autologous chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen, or BCMA, on malignant plasma cells. A patient's T cells are collected, genetically modified, expanded, and returned by infusion after lymphodepleting chemotherapy.
Carvykti uses a CAR design with two BCMA-binding domains. The product has demonstrated deep and durable responses in relapsed or refractory multiple myeloma, particularly after prior exposure to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.
The therapy is administered only through qualified treatment centers under the FDA's Risk Evaluation and Mitigation Strategy. Its principal safety risks include:
- Cytokine release syndrome, or CRS
- Immune effector cell-associated neurotoxicity syndrome, or ICANS
- Prolonged cytopenias and infections
- Hemophagocytic lymphohistiocytosis or macrophage activation syndrome
- Rare movement and neurocognitive disorders
- Secondary T-cell malignancies, a risk identified in the FDA's 2024 CAR-T class warning
What is the FDA regulatory status of Carvykti?
The FDA approved Carvykti on February 28, 2022, for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[1]
On April 5, 2024, the FDA expanded the indication to adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.[2]
This earlier-line indication changed the commercial profile of the product. It placed Carvykti in competition for patients before they receive multiple later-line therapies, where treatment volumes are larger and patients may be fitter enough to tolerate CAR-T treatment.
Key FDA milestones
| Date |
Event |
| February 2022 |
Initial U.S. approval after at least four prior lines |
| May 2022 |
European Commission authorization for relapsed or refractory multiple myeloma after at least three prior therapies |
| April 2024 |
U.S. expansion after at least one prior line and lenalidomide-refractory disease |
| 2024 |
FDA labeling incorporated class-level concerns regarding secondary T-cell malignancies associated with autologous CAR-T products |
How large is the ciltacabtagene autoleucel market?
The addressable market is expanding in two directions. The first is geographic expansion across the United States, Europe, Japan, and other major oncology markets. The second is movement from fourth-line use toward earlier treatment.
The U.S. multiple myeloma market includes more than 35,000 newly diagnosed patients annually, with a large proportion eventually receiving several lines of therapy. Carvykti does not address the entire population because treatment requires adequate organ function, referral to an authorized center, apheresis capacity, and the ability to tolerate lymphodepletion and CAR-T toxicities.
Commercial demand is strongest in:
- Patients with triple-class-exposed or triple-class-refractory disease.
- Patients refractory to lenalidomide after an earlier line.
- Patients seeking a fixed-duration treatment instead of continuous oral or infused therapy.
- Patients treated at high-volume transplant and cellular-therapy centers.
The market remains supply constrained. Manufacturing slots, apheresis scheduling, product release testing, and hospital capacity can delay treatment even when physicians select Carvykti.
What are Carvykti sales and the financial trajectory?
Janssen reported Carvykti sales of approximately $500 million in 2023. Sales reached roughly $1 billion in 2024, representing about a doubling year over year as the product gained broader U.S. use and expanded internationally.[3]
| Year |
Approximate global sales |
Commercial driver |
| 2022 |
About $134 million |
Partial-year launch |
| 2023 |
About $500 million |
Broader center activation and demand in later-line disease |
| 2024 |
About $1 billion |
Earlier-line U.S. approval and manufacturing expansion |
| 2025 onward |
Growth expected, subject to capacity |
Earlier-line penetration, international rollout, and production scale |
The earlier-line label is financially important because the eligible population is several times larger than the original fourth-line population. Revenue growth will depend less on price increases than on the number of patients treated.
Carvykti's list price in the United States is approximately $465,000 per treatment, before hospital costs, lymphodepletion, supportive care, and negotiated discounts. Total episode economics are higher because patients require apheresis, inpatient or closely monitored outpatient care, toxicity management, and long-term follow-up.
Janssen's economics are shared with Legend under their global collaboration. J&J commercializes the product outside Greater China, while Legend maintains significant economic participation and rights in Greater China. The agreement gives J&J access to a major oncology platform while allowing Legend to monetize a product without independently building a global commercial organization.
How does Carvykti compare with Abecma?
Carvykti's principal commercial competitor is idecabtagene vicleucel, marketed as Abecma by Bristol Myers Squibb and 2seventy bio.
| Attribute |
Carvykti |
Abecma |
| Active ingredient |
Ciltacabtagene autoleucel |
Idecabtagene vicleucel |
| Target |
BCMA |
BCMA |
| Initial U.S. approval |
2022 |
2021 |
| Earlier-line expansion |
2024, after at least one prior line in defined patients |
2024, after at least two prior lines in defined patients |
| Commercial position |
Strong efficacy and rapid demand growth |
Established first-mover position |
| Main constraint |
Manufacturing and treatment capacity |
Manufacturing, competition, and demand allocation |
| Company |
Janssen and Legend |
Bristol Myers Squibb and 2seventy bio |
In the CARTITUDE-4 study, Carvykti improved progression-free survival compared with standard regimens in lenalidomide-refractory patients after one to three prior lines.[4] In the KarMMa-3 study, Abecma improved outcomes compared with standard regimens in patients with two to four prior lines.[5]
Carvykti has generally held the stronger commercial growth profile, while Abecma retains an installed base and may compete effectively where manufacturing turnaround, physician familiarity, or payer contracting favors BMS.
Other competitors include bispecific antibodies targeting BCMA or GPRC5D, including teclistamab, elranatamab, and talquetamab. These products do not require individualized manufacturing and can be administered repeatedly, giving them an operational advantage. CAR-T therapies have a fixed treatment course and may offer deeper or more durable responses, but they require greater logistical infrastructure.
What patents protect ciltacabtagene autoleucel?
Carvykti is a biologic product and does not have conventional Orange Book patent listings. Biologic patent information is evaluated through the Purple Book and the Biologics Price Competition and Innovation Act, or BPCIA, rather than the small-molecule Orange Book framework.[6]
The relevant intellectual-property estate is expected to include several layers:
- CAR construct and dual-domain BCMA-binding architecture
- Nucleic acid sequences and viral-vector engineering
- T-cell transduction and expansion processes
- Cell-composition and product-quality specifications
- Manufacturing and cryopreservation methods
- Treatment methods for multiple myeloma
- Combination use with standard myeloma therapies
Public patent protection for a CAR-T product is rarely limited to one composition patent. Manufacturing patents can be commercially important because a biosimilar or competing cell therapy must reproduce a reliable process, not merely copy a chemical structure.
When does Carvykti lose exclusivity?
The relevant U.S. biologic exclusivity period is 12 years from first licensure under the Public Health Service Act. Because Carvykti was licensed in February 2022, statutory reference-product exclusivity generally extends to February 2034, subject to the specific calculation of first licensure and any regulatory interpretation.[1]
Patent expiration dates may extend beyond or fall before the statutory exclusivity date. The practical entry date for a competing product will depend on:
- The enforceable patent claims
- Patent-term adjustment or extension
- BPCIA patent litigation
- FDA approval timing
- Manufacturing readiness
- Whether a competitor uses the same or a non-infringing CAR design
A conventional generic is not an applicable pathway. Potential competitors would be biosimilars, interchangeable biologics where feasible, or next-generation BCMA-directed cell therapies. Autologous CAR-T products are technically difficult to characterize against a reference product, making biosimilar substitution more complex than substitution for a monoclonal antibody.
What generic and biosimilar entry risks exist?
Near-term generic erosion risk is low. Carvykti is an individualized living-cell product, and an abbreviated approval pathway would face analytical, clinical, and manufacturing challenges.
The more credible long-term threats are:
- Competing CAR-T products with different BCMA constructs.
- Allogeneic or off-the-shelf CAR-T products.
- BCMA bispecific antibodies with faster treatment initiation.
- GPRC5D-directed therapies that avoid BCMA resistance.
- Process patents that competitors design around.
- Pricing pressure from payers as multiple cellular and immune therapies become available.
The risk is therefore more likely to emerge through therapeutic substitution than through a classic biosimilar launch immediately after statutory exclusivity.
Which companies are challenging the Carvykti franchise?
The competitive field includes:
- Bristol Myers Squibb and 2seventy bio, with Abecma
- Johnson & Johnson and Legend Biotech, with Carvykti
- Johnson & Johnson, with teclistamab
- Pfizer, with elranatamab
- Roche and other developers pursuing BCMA or GPRC5D therapies
- Emerging biotechnology companies developing allogeneic CAR-T products
No major public Paragraph IV challenge applies in the same manner as it would to an Orange Book-listed small molecule. For Carvykti, the relevant legal risks are BPCIA patent litigation, construct-specific patent disputes, manufacturing claims, and competition from non-infringing cell therapies.
What manufacturing barriers support Carvykti's commercial position?
Manufacturing is both a constraint and a competitive barrier. The product requires:
- Leukapheresis collection.
- Shipment to a manufacturing facility.
- T-cell activation and genetic modification.
- Cell expansion and quality testing.
- Cryopreservation and return shipment.
- Lymphodepletion and infusion at a qualified center.
Janssen and Legend have invested in manufacturing expansion, including increased production capacity and additional sites intended to reduce turnaround time. The key commercial metrics are manufacturing success rate, vein-to-vein time, release capacity, and the number of active treatment centers.
Shorter turnaround times can increase revenue without changing price. They also reduce the risk that patients deteriorate before infusion, a material issue in aggressive or heavily pretreated multiple myeloma.
What licensing deal governs Carvykti?
Legend Biotech and Janssen entered a worldwide collaboration in 2017 for the development and commercialization of LCAR-B38M, the program that became Carvykti. Janssen obtained commercial rights outside Greater China, while Legend retained rights in Greater China and participates economically in the product.
The transaction gave Janssen access to Legend's BCMA CAR-T technology and gave Legend development, regulatory, and commercial support from a global pharmaceutical company. The arrangement remains central to the financial trajectory of both companies.
What litigation and settlement issues affect Carvykti?
Carvykti's litigation exposure is more likely to involve patent ownership, CAR construct rights, manufacturing methods, and competing cell therapies than Hatch-Waxman Paragraph IV litigation.
Relevant legal issues include:
- Ownership and inventorship of BCMA CAR technology
- Scope of claims covering tandem or dual BCMA-binding domains
- Patent enforcement against rival CAR-T constructs
- Trade-secret protection for manufacturing processes
- BPCIA information exchange and patent litigation
- Product-liability claims related to CRS, neurotoxicity, and secondary malignancies
No broad public settlement framework has converted Carvykti into a conventional generic-entry case. The primary commercial defense remains the combined strength of regulatory exclusivity, manufacturing know-how, treatment-center relationships, and clinical differentiation.
How strong is the Carvykti patent estate?
The estate is commercially strong but operationally more important than a single patent expiration date suggests. Product-specific claims may protect the CAR architecture, while process claims can raise the cost and complexity of replication.
Its strength is supported by:
- A differentiated dual-binding BCMA construct
- Regulatory approval in multiple jurisdictions
- Clinical data in earlier-line and heavily pretreated disease
- Manufacturing complexity
- A high barrier to treatment-center qualification
- Long biologic exclusivity from the 2022 U.S. license
Its principal vulnerabilities are construct redesign, non-infringing competing CARs, allogeneic platforms, and antibody therapies that offer comparable outcomes without individualized manufacturing.
Key Takeaways
- Carvykti is a leading BCMA-directed CAR-T therapy for multiple myeloma.
- U.S. approval expanded in April 2024 from heavily pretreated disease to selected patients after one prior line.
- Global sales increased from about $500 million in 2023 to roughly $1 billion in 2024.
- Manufacturing capacity and treatment-center throughput are the main short-term limits on revenue.
- Abecma is the principal CAR-T competitor, while bispecific antibodies pose the largest operational threat.
- Carvykti has no conventional Orange Book patent pathway because it is a biologic.
- U.S. biologic exclusivity generally extends to about February 2034, subject to the statutory first-licensure calculation.
- Generic substitution risk is low; competition from redesigned CAR-T products, bispecific antibodies, and allogeneic therapies is more important.
- Janssen and Legend's 2017 collaboration gives both companies exposure to the product's expansion and long-term commercialization.
FAQs About Ciltacabtagene Autoleucel
How much does Carvykti cost in the United States?
The U.S. list price is approximately $465,000 per treatment, excluding lymphodepletion, hospitalization, toxicity management, and other treatment-related costs.
Is Carvykti a biosimilar or a generic drug?
No. Carvykti is an autologous cellular biologic. Future competition is more likely to come from biosimilars, competing CAR-T products, or other immune therapies than from a conventional generic.
What is the main risk to Carvykti sales?
The main risk is not near-term patent expiry. It is competition from BCMA and GPRC5D bispecific antibodies, rival CAR-T therapies, manufacturing constraints, and safety-related treatment exclusions.
Does Carvykti have an Orange Book patent listing?
No conventional Orange Book listing applies. Carvykti is regulated as a biologic, with patent and exclusivity issues evaluated under the Purple Book and BPCIA framework.
Why is Carvykti commercially important to Legend Biotech?
Carvykti is Legend's leading commercial product and provides revenue participation through its Janssen collaboration. Its earlier-line approval materially increases the potential patient population and the value of Legend's BCMA CAR-T platform.
References
- U.S. Food and Drug Administration. (2022). FDA grants accelerated approval to ciltacabtagene autoleucel for relapsed or refractory multiple myeloma.
- U.S. Food and Drug Administration. (2024). FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma after one prior line of therapy.
- Johnson & Johnson. (2025). 2024 annual report.
- San-Miguel, J., et al. (2023). Ciltacabtagene autoleucel versus standard care in lenalidomide-refractory multiple myeloma. The New England Journal of Medicine.
- Rodriguez-Otero, P., et al. (2023). Idecabtagene vicleucel or standard regimens in relapsed and refractory multiple myeloma. The New England Journal of Medicine.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
